Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions

The results hit like a ton of bricks, and have critical implications for the recently FDA-approved Alzheimer’s blood test. Researchers were packed wall-to-wall at a conference in San Diego last month. They were there to hear some of the most highly anticipated results in Alzheimer’s research for years. The results were